Our Technologies
Angelpro develops proprietary AI-driven drug discovery platforms spanning small molecules, peptides, and traditional Chinese medicine, each powered by purpose-built computational models and deep learning architectures.
Our Technological Capabilities
Showcasing our core technology platforms from gene editing to protein folding
Small Molecules
End-to-end AI capabilities for small molecule drug discovery, from repurposing existing drugs to designing novel chemical entities with optimized pharmacological profiles.
Our AI platform identifies new therapeutic indications for existing approved drugs by analyzing large-scale molecular interaction networks, clinical data, and multi-omics signatures. By leveraging deep learning models trained on drug-target binding profiles and disease pathology datasets, we uncover hidden pharmacological relationships that enable rapid repositioning of known compounds for novel indications, significantly reducing development timelines and de-risking the path to IND.
Peptides
AI-driven peptide discovery and optimization platform, leveraging deep learning for sequence design, stability engineering, and pharmacological screening of peptide therapeutics.
Our AI-powered peptide engineering platform combines sequence-based deep learning with structural modeling to design novel peptide therapeutics. The system generates optimized peptide sequences with enhanced target binding affinity, improved metabolic stability, and favorable pharmacokinetic profiles. Through iterative rounds of computational design and scoring, we rapidly explore the vast peptide sequence space to identify candidates with the optimal balance of potency, selectivity, and drug-like properties.
Traditional Chinese Medicine
AI-powered platform for modernizing traditional Chinese medicine drug discovery, combining ancient pharmacological knowledge with cutting-edge computational methods for active compound identification and new drug development.
Our TCM discovery platform applies AI-powered natural language processing and knowledge graph mining to centuries of traditional Chinese medicine literature and clinical records. By cross-referencing historical formulation data with modern molecular databases and disease ontologies, the platform identifies promising TCM-derived compounds and modified formulations for new drug development under the Class 2.3 regulatory pathway, bridging traditional wisdom with contemporary pharmaceutical science.
Interested in our technology?
Contact our scientific team to learn how our AI platform can accelerate your drug discovery programs.
Contact Our Scientific Team